Access Insights 2023: Bill Roth Discusses Top Trends Impacting Executives in 2023
Bill Roth provides his thoughts on top trends impacting pharma's top executives.
In an interview with Nicholas Saraceno, Bill Roth, SVP, Managing Partner, Blue Fin Group, discusses top trends impacting executives in 2023 and what it will lead into for 2024.
Roth: I think what people are realizing is that they can't run their commercial strategies and silos anymore. They can't allow marketing to do their thing. It's the alignment of those functions that matter so much. That is actually harder than you'd think.
The base function of what I think our everyday roles are is that we align the groups. We help marketing understand what access means and vice versa. From there, they are trying to get their heads around PBMs, removal of the AmCap, the IRA, how you balance all of the discounts and fees, and try to drive utilization. There is no recipe that's out there.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
